What it is
A triple agonist that activates GIP, GLP-1, and glucagon receptors, combining appetite, insulin, and energy-expenditure pathways in one molecule.
Retatrutide5 MGMetabolic collection
5 MG per vial · Box of 10
An investigational triple agonist studied for activity at GIP, GLP-1, and glucagon receptors in metabolic research.
Secure checkout is available through PeptidePay and NOWPayments.
Product guide
A triple agonist that activates GIP, GLP-1, and glucagon receptors, combining appetite, insulin, and energy-expenditure pathways in one molecule.
A phase 2 obesity study reported an average 24.2% weight reduction at 48 weeks with the highest studied dose. Larger phase 3 research is intended to evaluate efficacy and safety further.
Research-use noticeThis catalogue summary is educational, not medical advice or a recommendation for use. For qualified laboratory research only—not for human, clinical, veterinary, or household use.